@phdthesis{Jazbutyte2007,
  author    = {Jazbutyte, Virginija},
  title     = {Differential role of estrogen receptor isoforms in the cardiovascular system of young and senescent rats},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-24247},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2007},
  abstract  = {Cardiovascular disease is the major cause of mortality morbidity in both men and women in industrialized countries. The incidence of cardiovascular diseases in pre-menopausal women is lower compared to age-matched men but the risk of heart diseases increases dramatically after the onset of menopause.Therefore, it has been postulated that female sex hormones play an important role in cardiovascular health in pre-menopausal women. In contrast to clinical data, which failed to show positive estrogen effects on cardiovascular system of post- menopausal women, extensive experimental studies indicated cardioprotective effects of estrogens in laboratory animals. The majority of experimental estrogen substitution studies were performed with young individuals, thus the effects of ageing remain neglected and are poorly understood. The present project is the first attempt to study the cardiac effects of each estrogen receptor isoform (estrogen receptor alpha (ERa) and estrogen receptor beta (ERb)) in adult ("menopausal") and senescent ("post- menopausal") hypertensive rats. The female senescent spontaneously hypertensive rats (SHR) served as a model system for age- associated hypertension in females whereas young individuals were used for control experiments. Young and senescent SHR rats were treated with 17b- estradiol as well as new estrogen receptor isoform selective ligands 16a-LE2 (ERa agonist) and 8b-VE2 (ERb agonist). The results showed different functions of both estrogen receptor isoforms in cardiovascular system: ERa attenuated cardiac hypertrophy but not hypertension whereas ERb could significantly reduce both, blood pressure and cardiac hypertrophy. Surprisingly, both agonists and 17b- estradiol were effective in young animals but not in senescent SHR rats. These findings match with the clinical data and could be related to altered estrogen metabolism in senescent rats, since estrogen plasma levels did not increase to measurable extent in senescent animals receiving estrogen. Estrogen is metabolized by several 17b- hydroxysteroid dehydrogenase isoforms. In the current study, 17b- hydroxysteroid dehydrogenase type 10 (17b- HSD10) was identified as a novel protein- protein interaction partner of estrogen receptor alpha ligand binding domain (ERaLBD) in human heart. Cellular localization experiments of ERa in the cardiac myocytes showed nuclear and cytosolic localization pattern which overlapped partially with that of cardiac mitochondria. 17b-HSD10 is localized only in mitochondria. Direct interaction of both proteins was confirmed by pull- down experiments where 17b-HSD10 could be co-precipitated with ERa. Interestingly, protein interaction could be detected only under estrogen- free conditions whereas the presence of estrogen in the system blocked this interaction. Enzymatic assay which was developed in our laboratory, helped to define functional relevance of this interaction. The data obtained from enzymatic assays and protein- protein interaction studies strongly suggest that estrogen receptor could play an important role in the control of intracellular (or mitochondrial) estogen metabolism. The second potential ERa interaction partner in the heart- bladder cancer associated protein 10 (BLCAP10) - was initially identified in non- invasive bladder cancer cell lines. BLCAP10 protein expression in the heart as well as its localization pattern in cardiac myocytes is shown in the last part of the theses. Due to perinuclear localization similarity with ERb, we conclude that BLCAP10 could interact with ERb rather than with ERa. Poor BLCAP10 protein overexpression and toxicity in both, bacteria and eukaryotic cells, suggested that BLCAP10 could be involved in cell- cycle and/ or protein expression control. In summary, the results showed that isoform selective activation of estrogen receptors exert divergent effects in the cardiovascular system both by upregulation of aMHC expression or by lowering blood pressure. Hormones were effective in young animals but had only minor effects in senescent rats. The new ERa protein- protein interaction partners identified during the project provide new information about estrogen receptor function in the heart and its possible role in the regulation of estrogen homeostasis.},
  subject      = {{\"O}strogene},
  language  = {en}
}
@phdthesis{Gnadt2010,
  author    = {Gnadt, Mirjam},
  title     = {Pharmacokinetic and pharmacodynamic characterization of inhaled β2 - agonists using the isolated human lung perfusion model},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-53910},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2010},
  abstract  = {The inhaled pharmacotherapy is fundamental in the management of obstructive lung diseases such as asthma bronchiale or chronic obstructive pulmonary disease. In this context short- and long-acting β2-agonists play a prominent role as relieve and control medication. Regarding the risk-benefit profile of an inhaled drug, the pattern of pulmonary deposition and the rate and extent of absorption into systemic circulation are essential parameters. New developments of drugs are characterized by high lung retention and improved efficacy. The aim of the present thesis was the parallel evaluation the pharmacokinetic (PK) and -dynamic (PD) properties of inhaled β2-agonists employing an isolated human lung perfusion model (IPL). The short-acting β2-agonist salbutamol and the newly developed ultra long-acting β2-agonist GW597901 were chosen for the analysis of pulmonary drug absorption and bronchodilation. In a pharmacokinetic enabling study an established human IPL setting was modified to monitor the pharmacokinetics of the β2-agonists by measuring the concentrations in perfusion fluid, lung tissue and BAL samples obtained during and after the experiments. The IPL model revealed differences in the pulmonary absorption behaviour of GW597901 and salbutamol. The lipophilic compound GW597901 was distributed to a lower extent into the perfusion fluid compared to the more hydrophilic compound salbutamol. The analyzed time profiles of nebulized salbutamol in the perfusate were consistent to with a clinical study if considering experimental conditions as the actual deposited doses and the differing volume of distribution. Thus, the suitability of the IPL model for the PK analysis of inhaled β2-agonists was confirmed. In a PK/PD study the human ex vivo model was employed for the first time for the evaluation of the clinical relevant bronchodilating effect induced by inhaled β2-agonists in addition to the analysis of their pharmacokinetics. Thereby the focus was to determine the onset and extent of bronchodilation. A new method was established to monitor changes in lung function parameters due to pharmacodynamic interventions over the duration of the experiment that allowed permanent online recording of the ventilation volume and lung mechanic parameters. Bronchial challenges with aerolised MCh were performed successfully in isolated ventilated human lung lobes, even though the responder rate was lower than expected despite high administered doses. The administration of the short acting agent salbutamol led to an immediate onset of action recognized as a sudden increase of the ventilation volumes. The bronchodilation following the application of GW597901 was observed delayed after about 6 min. Monitored lung function parameters considerably improved by both β2 - agonists in the IPL setting but not significantly different. Thus, in regard of the different applied doses GW597901 had a higher intrinsic activity and bronchodilating potency than salbutamol. The concentrations of salbutamol and GW597901 in the perfusate determined in the PK/PD study were significantly lower than those observed in the pharmacokinetic enabling study, while the tmax values and the course of the distribution profiles remained similar. Most likely, the application of nebulized MCh prior to the administration of the β2 - agonists had a substantial influence on their pharmacokinetic behaviour. It is yet not clear whether pharmacodynamic effects or molecular competition processes for the passage to the systemic circulation or both influenced the redistribution of the β2 - agonists as seen in the PK/PD study. The potential clinical relevance of this observation has to be further investigated. The development of pulmonary edema during the experiment was one limitation of the IPL model. For the determination of the onset of edema formation four potential biochemical markers, specifically surfactant-protein A (SP-A), angiotensin-converting enzyme (ACE), urea and lactate dehydrogenase, were measured in perfusion fluids. In this context, an ELISA method for the quantification of human SP-A in biological matrices was successfully established. The investigations showed that the concentrations of SP-A and ACE in the perfusate increased over time as a sign for lung tissue damage and correlated with the degree of edema formation. For the first time the IPL model was used for the evaluation of potential pulmonary edema marker and the results have shown that it is valuable tool for further investigations in this field. In conclusion, the pharmacokinetic and pharmacodynamic characterization of GW597901 and salbutamol was successfully achieved using the IPL model. This ex vivo methodology may contribute to further insights and understanding of the complex pharmacokinetic processes of inhaled β2 - agonists in the lung.},
  subject      = {Beta-2-Rezeptor},
  language  = {en}
}
@phdthesis{Kloeckner2013,
  author    = {Kl{\"o}ckner, Jessica Vanessa},
  title     = {Design Subtyp-selektiver Agonisten und Antagonisten muskarinischer Rezeptoren},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-77403},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {Die Subtypselektivit{\"a}t von Liganden f{\"u}r einzelne Rezeptoren, deren Aktivierung und die anschließende Signalweiterleitung sind bis heute weitestgehend ungekl{\"a}rt. Die hier synthetisierten Liganden-Gruppen sollen helfen, die verschiedenen Prozesse am muskarinischen Rezeptor und seinen Subtypen zu verstehen. Die Einzelprojekte werden im Folgenden vorgestellt. 1) Um mittels FRET-Mikroskopie den Einfluss von allosteren Modulatoren, die sich von W84 bzw. Naphmethonium ableiten, in Bezug auf die Konformations{\"a}nderung aktivierter Rezeptoren untersuchen zu k{\"o}nnen, wurden die bekannten allosteren Bausteine sowie eine Reihe neuer Derivate synthetisiert. Alle untersuchten Substanzen zeigten einen hemmenden Effekt auf die mit dem Agonisten Iper-oxo vorstimulierten Rezeptoren. Das heißt, die Verbindungen ließen sich als negative allostere Modulatoren charakterisieren. 2) Da Iperoxo aufgrund seiner großen agonistischen Aktivit{\"a}t ein interessantes Werkzeug f{\"u}r die Grundlagenforschung darstellt, war es von großer Bedeutung, eine schnelle und reproduzierbare Synthese zu gew{\"a}hrleisten. Ausgehend von Propargylalkohol wurde in einer Mannich-Reaktion 4-Dimethylamino-but-2-en-1-ol gebildet, was mit dem zuvor hergestellten 3-Nitro-Δ2-isoxazolin zur Iperoxo-Base umgesetzt wurde. Neben einer deutlichen Ausbeutesteigerung ist nun die Reproduzierbarkeit im Gegensatz zu der von Dallanoce et al. publizierten Synthese gew{\"a}hrleistet. 3) Um den Einfluss der Kettenl{\"a}nge der Hybride Iper-6-Phth und Iper-6-Naph auf die agonistische Aktivit{\"a}t und Subtypselektivit{\"a}t der Substanzen untersuchen zu k{\"o}nnen, wurde versucht, Hybride verschiedener Kettenl{\"a}ngen herzustellen. Dabei konnte Iper-4-Phth erhalten werden. 4) Weiterhin sollte der Einfluss der Alkylkette am Stickstoff-Atom auf die Wirksamkeit in Bezug auf Affinit{\"a}t und Zellantwort des Iperoxo-Molek{\"u}ls ohne allosteren Modulator analysiert werden. Hierzu wurden die N-alkylierten Iperoxo-Derivate mit den Kettenl{\"a}ngen C2 bis C10 synthetisiert.. Mithilfe von Radioligand-Bindungsstudien und der dynamischen Massenumverteilung sollte die konformative {\"A}nderung des Rezeptors durch Aktivierung und die Signalweiterleitung untersucht werden. Durch Verl{\"a}ngerung der N-Alkylkette zeigte sich ein Wirksamkeitsverlust, d. h. die Dosis-Wirkungs-Kurven der prozentualen Zellantwort wurden im Vergleich zu denen des Iperoxos nach rechts verschoben. In Untersuchungen an der Rezeptor-Mutante CHO-hM2-Y1043.33A zeigte sich zudem, dass f{\"u}r den maximalen Effekt eine deutlich h{\"o}here Konzentration der Iperoxo-Derivate ben{\"o}tigt wird, wobei dieser Wirksamkeitsverlust im Vergleich zum Rezeptor-Wildtyp f{\"u}r Iperoxo selbst am st{\"a}rksten ausgepr{\"a}gt ist. Allerdings weisen Iperoxo und seine N-alkylierten Derivate an dieser Mutante eine h{\"o}here intrinsische Aktivit{\"a}t auf als die Kontrollverbindungen Oxotremorin M, C1-IP-C1 und Acetylcholin. Weiterhin konnte gezeigt werden, dass Iperoxo ebenso wie Oxotremorin, Acetylcholin, aber auch die kurzkettigen Iperoxo-Derivate neben dem Gi-Signalweg auch den Gs-Weg aktivieren k{\"o}nnen, wohingegen die langkettigen Derivate eine Gi-Signalwegs-Selektivit{\"a}t aufweisen. 5) In Analogie zu den N-alkylierten-Iperoxo-Derivaten sollten Untersuchungen mit den Antagonisten N-Alkyl-Atropin und -Scopolamin durchgef{\"u}hrt werden. In beiden F{\"a}llen zeigte das N-Methyl-Derivat eine h{\"o}here Affinit{\"a}t zum Rezeptor als der jeweilige Antagonist selbst, was auf die durch Alkylierung generierte positive Ladung zur{\"u}ckzuf{\"u}hren ist. Durch Verl{\"a}ngerung der Alkylketten ist jeweils eine Abnahme der Affinit{\"a}t zu beobachten. Die Affinit{\"a}t findet ebenfalls in beiden F{\"a}llen mit dem Butyl-Derivat ihr Minimum. Der anf{\"a}ngliche Affinit{\"a}tsverlust l{\"a}sst sich durch die zunehmende sterische Hinderung des Molek{\"u}ls erkl{\"a}ren, der sp{\"a}tere Anstieg bei einer Alkylkette l{\"a}nger als C4 deutet auf eine Wechselwirkung dieser langen Alkylkette mit einer weiteren (allosteren) Bindungsstelle hin. 6) Ausgehend von Iperoxo sollten dualstere Liganden entwickelt werden, die durch geeignete allostere Modulatoren selektiv nur einen Rezeptor-Subtyp adressieren und diesen durch Iperoxo aktivieren sollten. Als allostere Bausteine sollten die M4-selektiven Thienopyridine und die M1-selektiven Chinolone verwendet werden. 7) Zur Fluoreszenzmarkierung sollte Iperoxo-Base zudem mit dem Farbstoff Py-1 umgesetzt werden.},
  subject      = {Muscarinrezeptor},
  language  = {de}
}
@phdthesis{Dolles2018,
  author    = {Dolles, Dominik},
  title     = {Development of Hybrid GPCR Ligands: Photochromic and Butyrylcholinesterase Inhibiting Human Cannabinoid Receptor 2 Agonists},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-163445},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2018},
  abstract  = {While life expectancy increases worldwide, treatment of neurodegenerative diseases such as AD becomes a major task for industrial and academic research. Currently, a treatment of AD is only symptomatical and limited to an early stage of the disease by inhibiting AChE. A cure for AD might even seem far away. A rethinking of other possible targets is therefore necessary. Addressing targets that can influence AD even at later stages might be the key. Even if it is not possible to find a cure for AD, it is of great value for AD patients by providing an effective medication. The suffering of patients and their families might be relieved and remaining years may be spent with less symptoms and restrictions. It was shown that a combination of hCB2R agonist and BChE inhibitor might exactly be a promising approach to combat AD. In the previous chapters, a first investigation of dual-acting compounds that address both hCB2R and BChE was illustrated (figure 6.1). A set of over 30 compounds was obtained by applying SARs from BChE inhibitors to a hCB2R selective agonist developed by AstraZeneca. In a first in vitro evaluation compounds showed selectivity over hCB1R and AChE. Further investigations could also prove agonism and showed that unwanted off-target affinity to hMOP receptor could be designed out. The development of a homology model for hCB2R (based on a novel hCB1R crystal) could further elucidate the mode of action of the ligand binding. Lastly, first in vivo studies showed a beneficial effect of selected dual-acting compounds regarding memory and cognition. Since these first in vivo studies mainly aim for an inhibition of the BChE, it should be the aim of upcoming projects to proof the relevance of hCB2R agonism in vivo as well. In addition, pharmacokinetic as well as solubility studies may help to complete the overall picture. Currently, hybrid-based dual-acting hCB2R agonists and selective BChE inhibitors are under investigation in our lab. First in vitro evaluations showed improved BChE inhibition and selectivity over AChE compared to tacrine.78 Future in vitro and in vivo studies will clarify their usage as drug molecules with regard to hepatotoxicity and blood-brain barrier penetration. Since the role of hCB2R is not yet completely elucidated, the use of photochromic toolcompounds becomes an area of interest. These tool-compounds (and their biological effect) can be triggered upon irradiation with light and thus help to investigate time scales and ligand binding. A set of 5-azobenzene benzimidazoles was developed and synthesized. In radioligand binding studies, affinity towards hCB2R could be increased upon irradiation with UV-light (figure 6.2). This makes the investigated compounds the first GPCR ligands that can be activated upon irradiation (not vice versa). The aim of upcoming research will be the triggering of a certain intrinsic activity by an "efficacy-switch". For this purpose, several attempts are currently under investigation: an introduction of an azobenzene moiety at the 2-position of the benzimidazole core already led to a slight difference in efficacy upon irradiation with UV light. Another approach going on in our lab is the development of hCB1R switches based on the selective hCB1R inverse agonist rimonabant. First in vitro results are not yet available (figure 6.3).},
  subject      = {Ligand <Biochemie>},
  language  = {en}
}
@phdthesis{Kucka2021,
  author    = {Kucka, Kirstin Michaela},
  title     = {Charakterisierung eines neuen Tumor Nekrose Faktor (TNF) Rezeptor 2 (TNFR2) Agonisten: Der heteromere, membranst{\"a}ndige Ligand Lymphotoxin α\(_2\)β},
  doi       = {10.25972/OPUS-24982},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-249824},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2021},
  abstract  = {Seit mehr als zwei Jahrzehnten ist bekannt, dass nicht nur der Tumor Nekrose Faktor-α (=TNF-α) sondern auch Lymphotoxin-α (=LTα) in Form von Trimeren an TNFR1 und TNFR2 binden kann. Durch diese F{\"a}higkeit an beide Rezeptoren zu binden, haben diese zwei Liganden eine essentielle Rolle in der Entwicklung und dem Verlauf von Autoimmunerkrankungen. Bereits mit Beginn der 1990er Jahren wurde gezeigt, dass LTα nicht nur in Form von Homotrimeren vorliegt, sondern auch mit dem verwandten TNF-Superfamilie Liganden Lymphotoxin β (=LTβ) Heterotrimere bilden kann. Hierbei lagern sich LTα und LTβ in Form von LTα2β und LTαβ2 zusammen. Die initialen Experimente mit diesen Heterotrimeren zeigten bereits Unterschiede von LTα2β und LTαβ2. W{\"a}hrend LTα2β wie LTα an den TNFR1 bindet, kann LTαβ2 weder an TNFR1 noch TNFR2 binden und interagiert mit einem eigenen Rezeptor namens Lymphotoxin β Rezeptor (=LTβR). Da bereits zwei Liganden (TNF und LTα) f{\"u}r TNFR1 und TNFR2 bekannt waren, wurde LTα2β bis heute nicht weiter charakterisiert. LTαβ2 hingegen war lange Zeit der einzige bekannte Ligand f{\"u}r den LTβR, weshalb die LTαβ2-LTβR-Interaktion ausf{\"u}hrlich untersucht wurde. Diese Arbeit fokusiert sich auf die Charakterisierung von LTα2β. Hierf{\"u}r wurde die einzige bekannte Eigenschaft aus den 90er Jahren von LTα2β n{\"a}mlich die Bindung an TNFR1 aufgegriffen und um die Rezeptoren TNFR2 und LTβR erweitert. Diese Arbeit zeigt, dass LTα2β nicht nur an den TNFR1, sondern auch an TNFR2 und schwach an LTβR bindet. Trotz der asymmetrischen Bindestellen kann membrangebundenes LTα2β TNFR1 und TNFR2 nicht nur binden, sondern ist auch in der Lage diese zu aktivieren. Diese Arbeit gibt erste Einblicke in die Komplexizit{\"a}t dieses Heterotrimers indem gezeigt wird, dass LTα2β sowohl in seiner l{\"o}slichen als auch in seiner membrangebundenen Form den TNFR1 aktivieren kann, w{\"a}hrend der TNFR2 nur durch das membranst{\"a}ndige LTα2β aktiviert wird. Aufgrund der aktivierenden Eigenschaften von membranst{\"a}ndigem LTα2β und LTαβ2 auf die murine (=mu) Panc02-Zelllinie wird ein ersten Ausblick auf m{\"o}gliche weitergehende Experimente in mausbasierten Modellen gegeben. Die erzielten Ergebnisse zeigen, dass mit membranst{\"a}ndigem LTα2β ein neuer TNFR2 Agonist gefunden wurde.},
  subject      = {Ligand},
  language  = {de}
}